Sanofi News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

11.09.24	Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study (EN, Sanofi-Aventis)
10.09.24	Media Update: ERS: Dupixent data reinforce clinically meaningful benefit from pooled analysis of two COPD phase 3 studies (EN, Sanofi-Aventis)
02.09.24	Sanofi: Tolebrutinib For NrSPMS Meets Primary Goal In HERCULES Trial; Fails In GEMINI Trial For RMS (RTTNews)
02.09.24	Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis (GlobeNewswire)
02.09.24	Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis (EN, Sanofi-Aventis)
02.09.24	Biotech Stocks Facing FDA Decision In September 2024 (RTTNews)
26.08.24	Media Update: ERS: New data highlight Sanofi’s scientific innovation and leadership in immune-mediated respiratory diseases (EN, Sanofi-Aventis)
09.08.24	Sanofi: Information concerning the total number of voting rights and shares - July 2024 (GlobeNewswire)
08.08.24	Sanofi : Sarclisa Induction Treatment Improves PFS In Transplant-Eligible Myeloma Patients (RTTNews)
08.08.24	Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant (GlobeNewswire)
08.08.24	Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant (EN, Sanofi-Aventis)
25.07.24	Press Release: Online availability of Sanofi’s half-year financial report for 2024 (EN, Sanofi-Aventis)
25.07.24	Press Release: Online availability of Sanofi’s half-year financial report for 2024 (GlobeNewswire)
25.07.24	Sanofi Q2 Profit Down, Sales Rise; Lifts FY24 Business EPS View (RTTNews)
25.07.24	Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded (GlobeNewswire)
25.07.24	Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded (EN, Sanofi-Aventis)
22.07.24	Sanofi: Information concerning the total number of voting rights and shares – June 2024 (GlobeNewswire)
18.07.24	Sanofi : ALTUVIIIO XTEND-Kids Phase 3 Data Transforming Severe Hemophilia A Treatment For Children (RTTNews)
17.07.24	Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A (GlobeNewswire)
17.07.24	Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A (EN, Sanofi-Aventis)
03.07.24	Regeneron, Sanofi: EU Approves Dupixent As First-ever Targeted Therapy For COPD Patients (RTTNews)
03.07.24	Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD (EN, Sanofi-Aventis)
03.07.24	Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD (GlobeNewswire)
28.06.24	Media Update: Frexalimab new phase 2 data showed reduction of key biomarker of nerve cell damage in relapsing MS (EN, Sanofi-Aventis)
26.06.24	Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM (EN, Sanofi-Aventis)
26.06.24	Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM (GlobeNewswire)
25.06.24	Media Update: Riliprubart one-year follow-up from phase 2 study underpin the potential as a first-in-class treatment in chronic inflammatory demyelinating polyneuropathy (EN, Sanofi-Aventis)
25.06.24	Press Release: Availability of the Q2 2024 Aide-mémoire (GlobeNewswire)
25.06.24	Press Release: Availability of the Q2 2024 Aide-mémoire (EN, Sanofi-Aventis)
21.06.24	Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee (EN, Sanofi-Aventis)
21.06.24	Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee (GlobeNewswire)
21.06.24	Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran (EN, Sanofi-Aventis)
21.06.24	Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran (GlobeNewswire)
20.06.24	Sanofi And Biovac Ink Manufacturing Partnership To Make Inactivated Polio Vaccines In Africa (RTTNews)
20.06.24	Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa (GlobeNewswire)
20.06.24	Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa (EN, Sanofi-Aventis)
12.06.24	Sanofi: Information concerning the total number of voting rights and shares – May 2024 (GlobeNewswire)
11.06.24	Regeneron, Sanofi Report FDA Approval Of Kevzara To Treat Active PJIA (RTTNews)
03.06.24	Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 (GlobeNewswire)
03.06.24	Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 (EN, Sanofi-Aventis)
01.06.24	Media Update: Sanofi update on Zantac litigation (EN, Sanofi-Aventis)
31.05.24	Sanofi Launches 2024 Employee Stock Purchase Plan - Quick Facts (RTTNews)
31.05.24	Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan (EN, Sanofi-Aventis)
31.05.24	Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan (GlobeNewswire)
31.05.24	Sanofi, Regeneron: Dupixent Recommended For EU Approval By CHMP To Treat COPD Patients (RTTNews)
31.05.24	Regeneron : FDA Extends Review Period For Dupixent As COPD Treatment By Three Month (RTTNews)
31.05.24	Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD (EN, Sanofi-Aventis)
31.05.24	Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD (GlobeNewswire)
31.05.24	Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation (GlobeNewswire)
31.05.24	Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation (EN, Sanofi-Aventis)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

18:01		Dow Jones aktuell: Dow Jones notiert am Mittag im Plus
17:58		Handel in Europa: STOXX 50 schliesst im Minus
17:58		Schwacher Handel: SMI schliesst mit Verlusten
17:58		Verluste in Europa: Euro STOXX 50 letztendlich leichter
17:58		SPI-Handel aktuell: SPI zum Handelsende leichter
17:58		Minuszeichen in London: FTSE 100 schwächelt zum Ende des Freitagshandels
16:01		NASDAQ-Handel NASDAQ 100 schwächelt zum Start des Freitagshandels